Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
and strength and depth in oncology
3
INNOVATION
Selected assets
Solid tumors
Hematology
KisqaliⓇ
HR+/HER2- BC (adj) NATALEE readout event-driven, expected
end 2022
Asciminib
CML 3L: submitted
CML 1L: Ph3 started
Canakinumab
177 Lu-PSMA-617
NSCLC adjuvant: Ph3 ongoing
mCRPC post-taxane: submitted
Iptacopan
PNH: Ph3 started
mCRPC pre-taxane: Ph3 started
Sabatolimab
HR-MDS: Ph2 STIMULUS-MDS-1
continues to PFS readout¹
mHSPC: Ph3 started
JDQ443 KRAS inhibitor 2/3L NSCLC: Ph3 start in H1 2022
TNO155 SHP2 inhibitor Solid tumors: multiple combinations being explored in ongoing trials
combinations
Tislelizumab
2L esophageal cancer: submitted
NSCLC: H1 2022 MAA submission, evaluation of US BLA
submission options ongoing. Multiple indications in Ph3
YTB323
CD19 CAR-T
Ph3 STIMULUS-MDS-2 ongoing
AML: Ph2 STIMULUS-AML-1 ongoing
r/r DLBCL: Ph2 (pivotal) start 2022
'Wild Cards' LXH254 (melanoma: combo Ph2, NSCLC combo Ph1), NIS793 (mPDAC: Ph3 started, colorectal cancer Ph2 initiating)
1. Planned DMC readout for CR completed, study continues blinded to PFS readout, with submission in 2022/2023 using PFS and/or OS outcomes of Ph2 and/or Ph3 trial
15 Investor Relations | Q3 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation